Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aymeric Ravel-Chapuis

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Trends in Molecular Medicine|May 10, 2022
Combinatorial therapies for rescuing myotonic dystrophy type 1 skeletal muscle defectsAymeric Ravel-Chapuis, Bernard J Jasmin
The Journal of Physiology|June 13, 2022
Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patientsAymeric Ravel-Chapuis, Elise Duchesne, Bernard J Jasmin
Human Molecular Genetics|September 1, 2022
Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific mannerNaomi S Misquitta, Aymeric Ravel-Chapuis, Bernard J Jasmin
Annals of the New York Academy of Sciences|November 1, 2003
Synapse-specific gene expression at the neuromuscular junctionAlexandre Méjat, Aymeric Ravel-Chapuis, Marie Vandromme, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 29, 2024
The AMPK allosteric activator MK-8722 improves the histology and spliceopathy in myotonic dystrophy type 1 (DM1) skeletal muscleAymeric Ravel-Chapuis, Chimène Fahmi, Jonathan Gobin, et al.
The EMBO Journal|February 17, 2007
Postsynaptic chromatin is under neural control at the neuromuscular junctionAymeric Ravel-Chapuis, Marie Vandromme, Jean-Luc Thomas, et al.
Molecular Psychiatry|February 19, 2026
Exercise mimetics as unexplored therapeutics for treating depressionNicholas Fabiano, Jess G Fiedorowicz, Aymeric Ravel-Chapuis, et al.
Human Molecular Genetics|July 9, 2018
Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse musclesAymeric Ravel-Chapuis, Ali Al-Rewashdy, Guy Bélanger, et al.
The Journal of Biological Chemistry|February 1, 2026
Disruptions of Cell Signaling Pathways in Myotonic Dystrophy Type 1 (DM1) Skeletal Muscle, their Pathogenic Impact and Potential for Combinatorial TherapeuticsAymeric Ravel-Chapuis, Shatha A Atieh, Chimène Fahmi, et al.
Human Molecular Genetics|November 18, 2021
A novel CARM1-HuR axis involved in muscle differentiation and plasticity misregulated in spinal muscular atrophyAymeric Ravel-Chapuis, Amir Haghandish, Nasibeh Daneshvar, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Trends in Molecular Medicine|May 10, 2022
Combinatorial therapies for rescuing myotonic dystrophy type 1 skeletal muscle defectsAymeric Ravel-Chapuis, Bernard J Jasmin
The Journal of Physiology|June 13, 2022
Pharmacological and exercise-induced activation of AMPK as emerging therapies for myotonic dystrophy type 1 patientsAymeric Ravel-Chapuis, Elise Duchesne, Bernard J Jasmin
Human Molecular Genetics|September 1, 2022
Combinatorial treatment with exercise and AICAR potentiates the rescue of myotonic dystrophy type 1 mouse muscles in a sex-specific mannerNaomi S Misquitta, Aymeric Ravel-Chapuis, Bernard J Jasmin
Annals of the New York Academy of Sciences|November 1, 2003
Synapse-specific gene expression at the neuromuscular junctionAlexandre Méjat, Aymeric Ravel-Chapuis, Marie Vandromme, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|November 29, 2024
The AMPK allosteric activator MK-8722 improves the histology and spliceopathy in myotonic dystrophy type 1 (DM1) skeletal muscleAymeric Ravel-Chapuis, Chimène Fahmi, Jonathan Gobin, et al.
The EMBO Journal|February 17, 2007
Postsynaptic chromatin is under neural control at the neuromuscular junctionAymeric Ravel-Chapuis, Marie Vandromme, Jean-Luc Thomas, et al.
Molecular Psychiatry|February 19, 2026
Exercise mimetics as unexplored therapeutics for treating depressionNicholas Fabiano, Jess G Fiedorowicz, Aymeric Ravel-Chapuis, et al.
Human Molecular Genetics|July 9, 2018
Pharmacological and physiological activation of AMPK improves the spliceopathy in DM1 mouse musclesAymeric Ravel-Chapuis, Ali Al-Rewashdy, Guy Bélanger, et al.
The Journal of Biological Chemistry|February 1, 2026
Disruptions of Cell Signaling Pathways in Myotonic Dystrophy Type 1 (DM1) Skeletal Muscle, their Pathogenic Impact and Potential for Combinatorial TherapeuticsAymeric Ravel-Chapuis, Shatha A Atieh, Chimène Fahmi, et al.
Human Molecular Genetics|November 18, 2021
A novel CARM1-HuR axis involved in muscle differentiation and plasticity misregulated in spinal muscular atrophyAymeric Ravel-Chapuis, Amir Haghandish, Nasibeh Daneshvar, et al.
Pageof 4